title: Antithrombotics in heart failure.
abstract: Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contribute to the high rate of adverse events and fatal outcomes. Many heart failure patients routinely receive antithrombotic therapy due to the presence of a specific indication for its use, like ischemic heart disease or atrial fibrillation. However, there is no solid evidence to support the routine use of antithrombotic agents in all heart failure patients. This article reviews the evidence for using antithrombotic therapy in heart failure patients.
authors.forename: Davor
authors.initials: D
authors.lastname: Miličić
authors.affiliation: Jure Samardzic, Department for Cardiovascular Diseases, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia, jure.samardzic@gmail.com.
authors.forename: Jure
authors.initials: J
authors.lastname: Samardžić
authors.forename: Mate
authors.initials: M
authors.lastname: Petričević
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents